Eiger Biopharmaceuticals Says On April 2, Received Notice From Nasdaq That Co's Common Stock Will Be Delisted From Nasdaq; Common Stock Is Expected To Begin Trading On Over-Counter Market On April 11
Portfolio Pulse from Benzinga Newsdesk
Eiger Biopharmaceuticals received a notice from Nasdaq on April 2 about the delisting of its common stock, which is expected to start trading on the Over-the-Counter market on April 11, according to an SEC filing.

April 03, 2024 | 8:49 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Eiger Biopharmaceuticals' common stock will be delisted from Nasdaq and is expected to trade on the Over-the-Counter market starting April 11.
Delisting from a major exchange like Nasdaq generally reflects negatively on a company's financial health and compliance with exchange requirements. This move to the Over-the-Counter market could lead to reduced visibility, liquidity, and investor confidence in EIGR's stock, likely causing a short-term negative impact on its price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100